Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Pharmacokinetics of hypoxic cell radiosensitizers: a review. [Mice; dogs; humans]

Journal Article · · Cancer Clin. Trials; (United States)
OSTI ID:6008044

The comparative pharmacokinetics of various nitroimidazole radiosensitizers in different species are reviewed. Radiosensitization is dependent upon the tumor concentration at the time of radiotherapy, whereas host toxicity, including peripheral neuropathy, appears to be related to the tissue exposure or area under the curve (AUC). Nitroimidazoles penetrate lipoid membranes by passive diffusion, the rate increasing with lipophilicity. Derivatives more hydrophilic than misonidazole penetrate nervous tissues comparatively slowly. They are eliminated mainly by renal clearance. Most plasma data for intravenous radiosensitizers can be described by a two-compartment open model. But in the mouse, the kinetics of misonidazole are dose dependent with increasing apparent t1/2 and AUC at higher doses due to saturable Michaelis-Menten kinetics for metabolism.

OSTI ID:
6008044
Journal Information:
Cancer Clin. Trials; (United States), Journal Name: Cancer Clin. Trials; (United States) Vol. 3:3; ISSN CCTRD
Country of Publication:
United States
Language:
English